3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Hemangioma
9
Melanoma
6
Hemangioma, Capillary
6
Breast Neoplasms
5
Sarcoma
3
Hemangiosarcoma
3
Fallopian Tube Neoplasms
3
Urinary Bladder Neoplasms
2
Prostatic Neoplasms
2
Pancreatic Neoplasms
2
Multiple Myeloma
2
Hemangioma, Cavernous, Central Nervous System
2
Carcinoma, Ovarian Epithelial
2
von Hippel-Lindau Disease
1
Uterine Cervical Neoplasms
1
Urethral Neoplasms
1
Ureteral Neoplasms
1
Ulcer
1
Tuberous Sclerosis
1
Triple Negative Breast Neoplasms
1
Stomach Neoplasms
1
Spinal Cord Neoplasms
1
Smoldering Multiple Myeloma
1
Skin Neoplasms
1
Sarcoma, Kaposi
1
Recurrent respiratory papillomatosis
1
Recurrence
1
Papilloma
1
Ovarian Neoplasms
1
Neuroblastoma
1
Interventions
Sunitinib
2
belzutifan
1
Propranolol
1
Nivolumab
1
Bevacizumab
1
4-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Hemangioblastoma
×
Propranolol
×
Clear all
NCT05424016
2023-12-13
PRO-HEB
Assistance Publique - Hôpitaux de Paris
Phase NA
Recruiting
85 enrolled